Alumino-Silicate Structural Formation during Alkali-Activation of Metakaolin: In-Situ and Ex-Situ ATR-FTIR Studies.

Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was used to demonstrate the reaction mechanisms of alkali-activated materials (AAMs) and the early stage of structure formation in the materials. The effects of different types of alkali activator solutions on the structure formation and reaction mechanisms of AAMs were studied. The results revealed that the main peaks of the ATR-FTIR spectra of the AAMs in the 1300-650 cm-1 range shifted to a low wavenumber with changing patterns, depending on the activator solution used, indicating that the dissolution and reorientation of metakaolin had occurred. Silica and alumina monomers were dissolved by the NaOH solution to produce crystalline zeolites. Although the reaction between metakaolin and Na2SiO3 solution is slow, the condensation between the Al-OH from metakaolin and the Si-OH from Na2SiO3 solution bonded the chain to be longer. Therefore, the Na2SiO3 solution acted as a template-bonded monomer, formed long chains of Si-O-Si and Si-O-Al, and produced an amorphous AAM structure. In the mixed solution, when the NaOH in it dissolved the Si and Al monomers, the Na2SiO3 in the solution also bonded with monomers and produced a complex structure. The different reaction that metakaolin had with different alkali activator solutions reflected the different phases, microstructures, and mechanical properties of the AAMs produced.

Sewage sludge ash contaminated with radiocesium: Solidification with alkaline-reacted metakaolinite (geopolymer) and Portland cement.

This study contributes toward developing measures for the disposal of radiocesium-contaminated sewage sludge ash (SSA). Here, we prepared two types of solidified bodies containing 30 wt% radiocesium-bearing SSA. The material used for the two solidified bodies were alkaline-reacted metakaolinite (geopolymer) and ordinary Portland cement (OPC). Cement has been used for solidification of low-level radioactive wastes, and geopolymer is a candidate of cement alternative materials. The characteristics of these solidified bodies were investigated by various aspects including mechanical strength, transformation of SSA components during solidification, and radiocesium confinement ability by leaching test. The compressive strength of geopolymer- and OPC-solidified bodies at 30 wt% SSA content was more than 40 MPa. After static leaching test at 60 °C, 137Cs was hardly leached out from the geopolymer-solidified bodies containing SSA at 30 wt% to ultrapure water (<0.1%), whereas more than 30% 137Cs was leached from the OPC-solidified bodies containing SSA at 30 wt% even though only ~9% of 137Cs in the SSA is soluble. These results strongly indicate that geopolymer is far superior to OPC for solidifying radiocesium-bearing SSA.

Pre-Injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test.

We studied the effect of pre-injury magnesium (Mg(2+)) treatment on hippocampal extracellular signal- regulated kinase (ERK) activation induced by lateral fluid-percussion (FP) brain injury, and on working and reference memory in the radial-arm maze test in rats subjected to such traumatic brain injury (TBI) (n = 56) or to sham injury (n = 12). In the ipsilateral hippocampus, an increase in the phospho-ERK level was detected at 10 min after injury in rats subjected to FP brain injury of moderate severity (1.9-2.0 atm) as compared to sham-injured controls (p < 0.01), and was maintained for at least 120 min after injury (p < 0.05). In the contralateral hippocampus, the phospho-ERK level was transiently increased at 10 min after injury but fell to nearly its basal level by 30 min. When MgCl(2) solution (150 micromol) was infused intravenously from 20 min to 5 min before injury (n = 4-5), brain injury-induced ERK activation was significantly inhibited in the ipsilateral hippocampus at 60 min but not at 10 min after injury. Mg(2+) treatment also significantly prevented injury- induced neuronal loss in the ipsilateral hippocampus (p < 0.05 vs. vehicle-treated, brain-injured controls). At 2 weeks after injury, Mg2+ treatment was found to have significantly prevented injury-induced impairments in working (p < 0.0001 vs. vehicle-treated, brain-injured controls) and reference memory (p < 0.05) in the radial-arm maze test. The present study demonstrates that pretreatment with Mg(2+) prevents post-traumatic hippocampal ERK activation and neuronal loss, and cognitive dysfunction in the radial-arm maze test.

Identification of addicsin/GTRAP3-18 as a chronic morphine-augmented gene in amygdala.

Using subtractive cloning, we identified a 1.4 kb mRNA that was ubiquitously expressed in various tissues; this mRNA was highly up-regulated in amygdala nuclei in mice when morphine was repeatedly administered but not when an opiate-receptor antagonist was co-administered. The mRNA encodes a 23 kDa protein, designated 'addicsin'. This contains two putative PKC-phosphorylation motifs and several hydrophobic regions, and was recovered in a soluble protein fraction of brain lysate. Its primary structure showed 98% identity with that of rat glutamate-transporter-associated protein 3-18 (GTRAP3-18), a putative modulator of neural glutamate-transporter EAAC1. Up-regulation of addicsin expression by morphine may affect glutamate uptake in the amygdala, causing mice to develop morphine tolerance and dependence.

[Meloxicam (Mobic): a review of its pharmacological and clinical profile].

Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity.